Riverpark Capital Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$2.5M Sell
2,325
-771
-25% -$737K 4.83% 5
2025
Q3
$2.36M Sell
3,096
-267
-8% -$199K 4.27% 6
2025
Q2
$2.62M Buy
3,363
+276
+9% +$214K 4.25% 6
2025
Q1
$2.55M Buy
3,087
+383
+14% +$319K 4.68% 6
2024
Q4
$2.09M Buy
2,704
+350
+15% +$290K 3.65% 6
2024
Q3
$2.09M Hold
2,354
3.79% 6
2024
Q2
$2.13M Buy
2,354
+173
+8% +$138K 2.82% 16
2024
Q1
$1.7M Buy
2,181
+459
+27% +$327K 2.33% 22
2023
Q4
$1M Buy
1,722
+735
+74% +$429K 1.53% 31
2023
Q3
$530K Buy
+987
New +$509K 0.96% 35

Other funds holding LLY

Riverpark Capital Management's LLY Position: Q4 2025 in Review

Riverpark Capital Management reduced its Eli Lilly (LLY) stake by 25% in Q4 2025, selling an estimated $737K and leaving 2,325 shares worth $2.5M. The position accounts for 4.83% of the portfolio, ranked #5.

Riverpark Capital Management first reported a position in LLY in Q3 2023 and has held it in 10 quarters since. The position peaked at $2.62M in Q2 2025. 4,429 funds tracked by Wall St. Rank hold LLY as of Q4 2025.

  • Riverpark Capital Management held 2,325 shares of Eli Lilly worth $2.5M as of Q4 2025.
  • Riverpark Capital Management sold 771 Eli Lilly shares in Q4 2025, an estimated $737K.
  • Eli Lilly made up 4.83% of Riverpark Capital Management's portfolio in Q4 2025, its #5 holding.
  • Riverpark Capital Management first reported a position in Eli Lilly in Q3 2023 and has held it in 10 quarters since.
  • Riverpark Capital Management's Eli Lilly position peaked at $2.62M in Q2 2025.
  • 4,429 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2025.

Based on Riverpark Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.